Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a post hoc analysis of the ANANKE study
Year: 2025
Type: article
Abstract: Extract Former or current smoking is common among adults with asthma [1], and past tobacco exposure has been associated with steroid insensitivity and greater disease severity [2–6]. However, the clinical impact of smoking history on response to biologic therapy remains uncertain, as most randomized trials exclude smokers. We evaluated the long-term effectiveness of benralizumab in former smokers with severe eosinophilic asthma (SEA) versus never-smokers in a post hoc analysis of the ANANKE real-world study.
Source: ERJ Open Research
Authors: Gianenrico Senna, Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Laura Malerba, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Alessandra Vultaggio, Maria D'Amato, Marco Caminati
Institutions: University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, A. O. Ordine Mauriziano di Torino, University of Turin, Aziende Socio Sanitaria Territoriale Rhodense, University of Foggia, University of Siena, Humanitas University, Fondazione Humanitas per la Ricerca, IRCCS Humanitas Research Hospital, Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, University of Milan, Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo, Ospedale Antonio Cardarelli, University of Cagliari, Ospedale Papa Giovanni XXIII, AstraZeneca (Italy), AULSS 2 Marca Trevigiana, Magna Graecia University, University of Rome Tor Vergata, Policlinico Tor Vergata, Ospedale Generale Regionale Francesco Miulli, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, University of Florence, Federico II University Hospital, Ospedale Monaldi
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $808
Funder: AstraZeneca
OpenAlex ID: W4416746692